Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GMED's Cash to Debt is ranked higher than
93% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. GMED: No Debt )
GMED' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.86
GMED's Equity to Asset is ranked higher than
90% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. GMED: 0.86 )
GMED' s 10-Year Equity to Asset Range
Min: 0.83   Max: 0.88
Current: 0.86

0.83
0.88
Interest Coverage No Debt
GMED's Interest Coverage is ranked higher than
90% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. GMED: No Debt )
GMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 17.81
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.31
GMED's Operating margin (%) is ranked higher than
98% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. GMED: 28.31 )
GMED' s 10-Year Operating margin (%) Range
Min: 23.4   Max: 30.43
Current: 28.31

23.4
30.43
Net-margin (%) 18.63
GMED's Net-margin (%) is ranked higher than
95% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. GMED: 18.63 )
GMED' s 10-Year Net-margin (%) Range
Min: 15.79   Max: 19.13
Current: 18.63

15.79
19.13
ROE (%) 17.13
GMED's ROE (%) is ranked higher than
91% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. GMED: 17.13 )
GMED' s 10-Year ROE (%) Range
Min: 15.98   Max: 43.04
Current: 17.13

15.98
43.04
ROA (%) 14.52
GMED's ROA (%) is ranked higher than
96% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. GMED: 14.52 )
GMED' s 10-Year ROA (%) Range
Min: 13.54   Max: 36.91
Current: 14.52

13.54
36.91
ROC (Joel Greenblatt) (%) 72.98
GMED's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. GMED: 72.98 )
GMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 59.22   Max: 139.86
Current: 72.98

59.22
139.86
» GMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GMED Guru Trades in Q4 2013

Joel Greenblatt 127,089 sh (New)
Jim Simons 273,600 sh (New)
Steven Cohen 1,016,020 sh (+86.94%)
Paul Tudor Jones 24,700 sh (+85.71%)
Ronald Muhlenkamp 112,875 sh (+20.33%)
Chuck Royce Sold Out
RS Investment Management 2,430,383 sh (-10.17%)
» More
Q1 2014

GMED Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
RS Investment Management 2,407,467 sh (-0.94%)
Joel Greenblatt 107,520 sh (-15.4%)
Jim Simons 181,113 sh (-33.8%)
Ronald Muhlenkamp 51,480 sh (-54.39%)
Steven Cohen 343 sh (-99.97%)
» More
Q2 2014

GMED Guru Trades in Q2 2014

Paul Tudor Jones 28,222 sh (New)
Joel Greenblatt 920,280 sh (+755.92%)
Jim Simons 786,400 sh (+334.2%)
Steven Cohen 351,000 sh (unchged)
RS Investment Management Sold Out
Ronald Muhlenkamp Sold Out
» More
Q3 2014

GMED Guru Trades in Q3 2014

Paul Tudor Jones 52,495 sh (+86.01%)
Joel Greenblatt 1,165,867 sh (+26.69%)
Jim Simons 852,500 sh (+8.41%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 26.69%0.05%$18.14 - $23.58 $ 24.2318%1165867
Joel Greenblatt 2014-06-30 Add 755.92%0.25%$22.75 - $26.95 $ 24.230%920280
Ronald Muhlenkamp 2014-06-30 Sold Out 0.24%$22.75 - $26.95 $ 24.230%0
Ronald Muhlenkamp 2014-03-31 Reduce -54.39%0.22%$19.59 - $26.64 $ 24.233%51480
Ronald Muhlenkamp 2013-12-31 Add 20.33%0.07%$17.16 - $19.84 $ 24.2331%112875
Joel Greenblatt 2013-12-31 New Buy0.06%$17.16 - $19.84 $ 24.2331%127089
Joel Greenblatt 2013-09-30 Sold Out 0.01%$16.75 - $18.06 $ 24.2340%0
Ronald Muhlenkamp 2013-03-31 New Buy0.29%$10.49 - $15 $ 24.2381%95935
Joel Greenblatt 2013-03-31 New Buy0.01%$10.49 - $15 $ 24.2381%11069
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.90
GMED's P/E(ttm) is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. GMED: 26.90 )
GMED' s 10-Year P/E(ttm) Range
Min: 12.95   Max: 35.54
Current: 26.9

12.95
35.54
P/B 4.13
GMED's P/B is ranked higher than
69% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. GMED: 4.13 )
GMED' s 10-Year P/B Range
Min: 2.45   Max: 4.94
Current: 4.13

2.45
4.94
P/S 5.01
GMED's P/S is ranked higher than
64% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. GMED: 5.01 )
GMED' s 10-Year P/S Range
Min: 2.48   Max: 5.61
Current: 5.01

2.48
5.61
PFCF 25.78
GMED's PFCF is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 25.78 )
GMED' s 10-Year PFCF Range
Min: 18.52   Max: 39.26
Current: 25.78

18.52
39.26
EV-to-EBIT 14.84
GMED's EV-to-EBIT is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. GMED: 14.84 )
GMED' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 21.3
Current: 14.84

6.7
21.3
Current Ratio 6.66
GMED's Current Ratio is ranked higher than
90% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. GMED: 6.66 )
GMED' s 10-Year Current Ratio Range
Min: 5.97   Max: 10.12
Current: 6.66

5.97
10.12
Quick Ratio 5.60
GMED's Quick Ratio is ranked higher than
90% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. GMED: 5.60 )
GMED' s 10-Year Quick Ratio Range
Min: 4.71   Max: 8.29
Current: 5.6

4.71
8.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.12
GMED's Price/Net Cash is ranked higher than
92% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 11.12 )
GMED' s 10-Year Price/Net Cash Range
Min: 6.32   Max: 18.33
Current: 11.12

6.32
18.33
Price/Net Current Asset Value 7.85
GMED's Price/Net Current Asset Value is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 7.85 )
GMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.3   Max: 9.53
Current: 7.85

4.3
9.53
Price/Tangible Book 4.52
GMED's Price/Tangible Book is ranked higher than
77% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. GMED: 4.52 )
GMED' s 10-Year Price/Tangible Book Range
Min: 2.65   Max: 5.51
Current: 4.52

2.65
5.51
Price/Median PS Value 1.23
GMED's Price/Median PS Value is ranked higher than
71% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. GMED: 1.23 )
GMED' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.4
Current: 1.23

0.62
1.4
Price/Graham Number 2.32
GMED's Price/Graham Number is ranked higher than
86% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 2.32 )
GMED' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 2.96
Current: 2.32

1.24
2.96
Earnings Yield (Greenblatt) 6.70
GMED's Earnings Yield (Greenblatt) is ranked higher than
91% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. GMED: 6.70 )
GMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.7   Max: 15
Current: 6.7

4.7
15

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GM0N.Germany,
Globus Medical Inc was incorporated in Delaware in March 3, 2003. The Company is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. It is currently focused on implants that promote healing in patients with spine disorders. All of its products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company's Innovative Fusion products address a spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. It currently offers over 120 products for the treatment of spine disorders. Products in Innovative Fusion includes: CREO, a convenient non-threaded locking cap design that eases building of thoracolumbar fixation constructs to readily adapt to the patient's anatomy and condition, for a range of clinical applications. XPAND, FORTIFY, FORTIFY-I corpectomy devices that incorporate smooth expansion capability, have a range of size options for optimal fit, and are manufactured from titanium or radiolucent polyetheretherketone. COALITION and INDEPENDENCE stand-alone interbody fusion devices, simplify the surgical technique by reducing steps and hardware while providing confident stabilization. Disruptive Technologies represent a shift in the treatment of spine disorders by allowing for novel surgical procedures, improvements to existing surgical procedures, and the treatment of spine disorders by new physician specialties, and surgical intervention earlier in the continuum of care. Products in Disruptive Technologies includes: MIS products which enable a surgeon to perform a procedure less invasively to minimize tissue disruption and maximize native anatomy, for patient recovery and fewer approach-related complications. For example, MARS 3V retractor system facilitates smaller incisions with the use of positionable radiolucent retractor blades to access the surgical site and to allow both direct and radiographic visualization. CALIBER, RISE and recently launched LATIS expandable interbody spacers are designed for reliable, minimally disruptive delivery through small MIS incisions with streamlined implants and instruments. REVOLVE pedicle screw system is designed for MIS screw and rod insertion through small incisions, and utilizes a convenient non-threaded locking cap design. TRANSITION, provide for stabilization that is less rigid than traditional pedicle screw systems for more natural load distribution to help promote fusion while maintaining stability. Other products included are SECURE-C, SECURE-CR, KINEX, MICROFUSE, SHIELD, AFFIRM, among others. Company's competitors include: Medtronic, the DePuy Synthes Companies, Stryker and NuVasive. Alphatec Spine, Orthofix International, Zimmer, LDR, among others. As of December 31, 2013, the Company owned 188 issued U.S. patents and had applicat
» More Articles for GMED

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
NYSE stocks posting largest volume increases Dec 17 2014
Globus Medical to Redefine Spinal Fusion with ALTERA Nov 14 2014
Globus Medical Announces ALTERA™ Minimally Invasive Articulating Expandable Spacer Nov 12 2014
Coverage initiated on Globus Medical by Brean Capital Nov 11 2014
Globus Medical Reports 2014 Third Quarter Results Oct 30 2014
Globus Medical Inc Earnings Call scheduled for 5:30 pm ET today Oct 30 2014
GLOBUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Oct 30 2014
Globus Medical Reports 2014 Third Quarter Results Oct 30 2014
Q3 2014 Globus Medical Inc Earnings Release - After Market Close Oct 30 2014
GLOBUS MEDICAL INC Files SEC form 8-K, Other Events Oct 24 2014
Globus Medical Announces Acquisition of Transplant Technologies of Texas Oct 23 2014
Globus Medical Announces Acquisition of Transplant Technologies of Texas Oct 23 2014
Globus Medical Schedules Third Quarter 2014 Earnings Release and Conference Call Oct 23 2014
Globus Medical Schedules Third Quarter 2014 Earnings Release and Conference Call Oct 15 2014
Globus Medical Schedules Third Quarter 2014 Earnings Release and Conference Call Oct 15 2014
Globus Medical Announces the SILC Fixation System for the Deformity Market Oct 09 2014
Globus Medical (GMED) Downgraded From Buy to Hold Sep 17 2014
Globus Medical to Present at the 2014 Morgan Stanley Global Healthcare Conference Sep 02 2014
Globus Medical (GMED): Moving Average Crossover Alert Aug 26 2014
GLOBUS MEDICAL INC Financials Aug 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK